9 Meters Biopharma (9 Meters Biopharma) Forward PE Ratio : 0.00 (As of May. 31, 2024)

View and export this data going back to 2016. Start your Free Trial

What is 9 Meters Biopharma Forward PE Ratio?

9 Meters Biopharma's Forward PE Ratio for today is 0.00.

9 Meters Biopharma's PE Ratio without NRI for today is 0.00.

9 Meters Biopharma's PE Ratio for today is 0.00.

9 Meters Biopharma Forward PE Ratio Historical Data

The historical data trend for 9 Meters Biopharma's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

9 Meters Biopharma Forward PE Ratio Chart

9 Meters Biopharma Annual Data

Trend

Forward PE Ratio

9 Meters Biopharma Quarterly Data

Forward PE Ratio

Competitive Comparison of 9 Meters Biopharma's Forward PE Ratio

For the Biotechnology subindustry, 9 Meters Biopharma's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

9 Meters Biopharma's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 9 Meters Biopharma's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where 9 Meters Biopharma's Forward PE Ratio falls into.

9 Meters Biopharma Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

9 Meters Biopharma (OTCPK:NMTRQ) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

9 Meters Biopharma Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of 9 Meters Biopharma's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

9 Meters Biopharma (9 Meters Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 9 Meters Biopharma Inc (OTCPK:NMTRQ) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

4509 Creedmoor Road, Suite 201, Raleigh, NC, USA, 27612

Website

https://www.9meters.com

9 Meters Biopharma Inc is a clinical-stage biopharmaceutical company focused on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. Its products include NM-002, Larazotide, NM-003, and others.

Executives

Bethany Sensenig	officer: Chief Financial Officer	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
John Temperato	director, officer: Chief Executive Officer	C/O MELINTA THERAPEUTICS,INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Mark A Sirgo	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Michael T. Constantino	director	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Samantha Ventimiglia	director	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Edward J Sitar	officer: Chief Financial Officer	39 FLAMING ARROW ROAD, MAHWAH NJ 07430
Orbimed Israel Biofund Gp Limited Partnership	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
Yehuda Michael Rice	director	155 WALNUT STREET, ENGLEWOOD NJ 07631
Nissim Darvish	director, 10 percent owner	C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Orbimed Israel Gp Ltd.	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Sandeep Laumas	director, officer: Executive Chairman	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Jay P. Madan	director, officer: President	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Roy Proujansky	director	144 PAU NEL DRIVE, LANDENBERG PA 19350
Christopher P. Prior	director, officer: Chief Executive Officer	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
June Sherie Almenoff	officer: COO and Chief Medical Officer	C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019